The importance of the fatty acid transporter L-Carnitine in non-alcoholic fatty liver disease (NAFLD)
Track patterns and share them with your prescriber so doses can be adjusted safely
The companies will coordinate to improve access to prescribed treatment and integrated behavioral support tools that complement prescribed GLP-1 treatments
Retatrutide at a glance Not approved research chemical Type Investigational drug in clinical trials, not yet approved Also called LY3437943 Interest in it for Obesity / weight loss and type 2 diabetes Evidence Human clinical trials underway
[DOI] [PMC free article] [PubMed] [Google Scholar] 23.Teras L.R., Patel A.V., Wang M., Yaun S.-S., Anderson K., Brathwaite R., Caan B.J., Chen Y., Connor A.E., Eliassen A.H., et al
2024 Oct;44(10):1528-1539